ARTIMPLANT YEAR-END REPORT 2010

ARTIMPLANT YEAR-END REPORT 2010

 

Västra Frölunda, Sweden, February 10, 2011


  · Net revenue for the fourth quarter amounted to SEK 3.5 million (5.8)
and for January-December SEK 18.5 million (24.0).*
  · The net loss for the fourth quarter totaled SEK 7.4 million (5.4)
and for January-December SEK 22.4 million (18.6).  
  · Earnings per stock unit for the fourth quarter amounted to SEK -0.07
(-0.09) and for January-December SEK -0.32 (-0.31).
  · Artimplant's own sales as a proportion of total sales continued to
increase and were equivalent to 70% (60) of product sales for the fourth
quarter, equivalent to 61% (37) for the full year.
  · Compared to 2009, Artimplant's own sales in the USA more than
doubled whilst revenue from license sales was halved.
  · Artimplant's rights issue was subscribed up to 189% and generated
capital input for the Company of approximately SEK 38.5 million before
issue costs.
  · Artimplant's strategy has been focused on marketing with increased
intensity in own sales in the USA.
  · Artimplant implemented staff cutbacks in Sweden during the fall of
2010 equivalent to an annual saving of approximately SEK 5 million once
the periods of notice came to an end. At the same time the Company has
employed more product specialists in the USA.
  · The Board proposes that no dividend be paid for 2010.

Events after the period-end

  · The launch of the new Artelon® Tissue Reinforcement products has
commenced.

N. B. This is a translation from Swedish. The Swedish version shall
always take precedence.

Artimplant will hold a telephone conference by reason of this report on
February 10, 2011 at 11 am (CET). For further information see
www.artimplant.com.

* Figures in brackets refer to the corresponding period last year.

For further information, please contact: Hans Rosén, CEO, phone 46
(0)31-746 56 00, 46 (0)708 58 34 70,
hans.rosen@artimplant.com (hans.rosen@artimplant.com)

Lars-Johan Cederbrant, CFO, phone 46 (0)31-746 56 54, 46 (0)703 01 68
54,
lars-johan.cederbrant@artimplant.com (lars-johan.cederbrant@artimplant.c
om)

Further information is available at
www.artimplant.com (http://www.artimplant.com). To subscribe to future
press releases please go to
www.artimplant.com/investors-media/subscribe-to-press-releases.html (htt
p://www.artimplant.com/investors-media/subscribe-to-press-releases.html)